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Abstract: B-cell depletion is a new strategy for treating patients with rheumatoid arthritis (RA). 
In the past years, several studies have proven the efﬁ  cacy of anti-CD20 mediated B-cell depletion 
with rituximab (Mabthera®) in RA patients who failed TNF-blocking therapy. The important role 
of B-cells in the pathogenesis of RA is deducted from the speciﬁ  c detection of autoantibodies in 
RA and inﬁ  ltration of B-cells and plasma cells in inﬂ  amed synovium. Pharmacological studies 
in RA patients treated with rituximab showed that half-life was approximately 3 weeks leading 
to a 6- to 8-month period of B-cell depletion in peripheral blood. Rituximab treatment led to 
signiﬁ  cant improvements in disease activity of RA patients and the current review summarizes 
the results from phase III, randomized clinical trials that have been performed. Lastly, data 
on safety and quality of life are summarized. Although relatively low numbers of RA patients 
have been treated and long-term data are lacking, current data thus far suggest a relatively good 
safety proﬁ  le for rituximab. Future studies will need to focus on predicting responsiveness to 
rituximab, investigating efﬁ  cacy of re-treatment with rituximab and extending data on safety 
and patient-focused outcomes.
Keywords: rheumatoid arthritis, B-cell depletion, rituximab, anti-CD20 monoclonal antibodies
The ﬁ  rst B-cell depleting agent, rituximab, was approved in 1997 for combination treat-
ment of CD20+ B-cell non-Hodgkin lymphoma (Coifﬁ  er et al 2002). In 2001, based on 
the premise that autoantibodies derived from B-cell-derived antibody-secreting cells 
were closely associated with disease pathogenesis, the ﬁ  rst study was published show-
ing promising effects of rituximab in the treatment of patients with rheumatoid arthritis 
(RA) (Edwards and Cambridge 2001). Because circulating autoantibodies are a common 
feature in several other auto-immune diseases as well, B-cell depleting therapies are 
now widely used in clinical trials assessing the safety and efﬁ  cacy of this treatment in 
a variety of systemic and organ-speciﬁ  c auto-immune diseases (Table 1).
Rituximab is a therapeutic agent categorized in the group of “biologicals”. It is a 
monoclonal antibody directed against the CD20 transmembrane protein present on 
B-cells. It is generally accepted that the CD20 protein functions as a channel regulator 
of ion inﬂ  ux (Ernst et al 2005) and that this membrane-bound protein is speciﬁ  cally 
found on the membrane of B-cells but is not expressed on stem cells nor on terminally-
differentiated plasma cells.
The current review addresses the expanding role of B-cell depleting therapy in the 
treatment of RA patients in rheumatologic practice. In this review, we focus on the 
role of B-cells in the pathogenesis of RA, on pharmacological aspects of rituximab 
and on results from clinical trials investigating rituximab in RA patients, including 
safety, efﬁ  cacy and quality of life studies.
Management of RA
Prominent symptoms of RA are symmetrical arthritis of multiple joints, mostly of the 
hands and feet, typically accompanied by morning stiffness. In the long term, RA leads Biologics: Targets & Therapy 2007:1(4) 326
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to joint destruction and increased disability (Isenberg et al 
2005). Because RA patients have a systemic, chronic and 
progressive disease, they usually require long-term immuno-
suppressive treatment. Generally, treatment of RA patients is 
instituted with a single or combination of Disease Modifying 
Anti-Rheumatic Drugs (DMARDs), of which methotrexate 
is currently seen as the anchor drug. Several studies have 
shown that failure rates for conventional DMARD therapy 
can accumulate over a follow-up period of 5 years to up to 
75% (Maetzel et al 2000; Aletaha and Smolen 2002; van der 
Kooij et al 2007). In a Dutch treatment strategy study, the 
so-called BeSt study, which investigated treatment strate-
gies in early RA, approximately 25% of the patients failed 
on step-up or combination DMARD treatment after 2 years 
of follow-up (Goekoop-Ruiterman et al 2007). From this 
perspective, the majority of RA patients will eventually 
fail conventional DMARD therapy, after which patients 
are candidates for treatment with biologicals, notably with 
anti-cytokine treatment directed against TNF (tumor necrosis 
factor) (Inﬂ  iximab®, Etanercept®, Adalimumab®). Currently 
most of the evidence for treating DMARD refractory RA is 
derived from treatment with TNF-blocking agents, which 
were the ﬁ  rst biologicals to be approved in this category 
of patients (Maini et al 1999; Weinblatt et al 1999, 2003; 
Bathon et al 2000). The success of speciﬁ  cally targeting 
TNF cytokines in RA patients has augmented the efforts to 
speciﬁ  cally target other components of the immune system 
in RA patients. Furthermore, it is estimated that one third 
of the RA patients eventually fail TNF-blocking agents 
(Tsokos 2004), which supports the need for new therapies 
to control disease activity in refractory RA. Newly emerging 
biologicals include B-cell depleting agents, ie, anti-CD20 
monoclonal antibodies (rituximab, HuMax-CD20®) and 
anti-CD22 monocolonal antibodies (Epratuzumab®), T-cell 
activation blockade through monoclonal antibodies against 
CTLA-4 (Orencia®, Abatacept®) and IL-6 receptor blockade 
(Tocilicumab®, Actemra®). While most of these biologicals 
are currently investigated in phase II and III trials or have 
recently been approved, the B-cell depleting agent rituximab 
has now been approved for treating RA patients refractory to 
TNF-blockade since 2006 (Approval Rituxan 2007; Mabthera 
2007). The success of B-cell depleting therapy in RA 
Table 1 Diseases associated with autoantibodies and the usage of rituximab
Autoimmune diseases Target organ(s) Rituximab 
treatment under 
investigation?
Inﬂ  ammatory
diseases
Target organ(s) Rituximab 
treatment under 
investigation?
Rheumatoid arthritis Joints yes Henoch-Schonlein 
purpura
Vasculature, 
kidney
yes
Systemic lupus erythematosus Systemic yes Chronic graft rejection Graft yes
Sjogren’s syndrome Salivary gland yes Immunoglobulin A 
nephropathy
Kidney no
ANCA-associated vasculitis Vasculature yes Atopic dermatitis Skin no
Antiphospholipid syndrome Vasculature yes Asthma Lung no
Idiopathic thrombocytopenia Platelets yes Allergy Skin, lung, gut no
Autoimmune haemolytic anaemia Red blood cells yes
Guillain-Barre syndrome Peripheral nervous 
system
yes Systemic sclerosis Connective 
tissue
no
Autoimmune thyroiditis Thyroid gland yes Multiple sclerosis Central nervous 
system
no
Pemphigus vulgaris Skin, mucous 
membranes
yes Lyme neuroborreliosis Central nervous 
system
no
Myasthenia gravis Skeletal muscle yes Ulcerative colitis Large intestine no
Chronic immune polyneuropathy Peripheral nervous 
system
no Interstitial lung disease Lung no
Type I diabetes Pancreatic islet cells no
Addison’s disease Adrenal gland no
Membranous glomerulopathy Kidney no
Goodpasture’s syndrome Lung, kidney no
Autoimmune gastritis Stomach no
Pernicious anaemia Stomach no
Primary biliary cirrhosis Liver no
Dermatomyositis-polymyositis Skeletal muscle, skin no
Celiac disease Small intestine noBiologics: Targets & Therapy 2007:1(4) 327
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patients has underscored the important role of B-cells in the 
pathophysiology of RA.
B-cells are critically involved
in the pathogenesis of RA
RA shares a common immune abnormality with other rheu-
matic diseases, such as systemic lupus erythematodes (SLE), 
Sjogren’s syndrome (SS) and Wegener granulomatosis 
(WG), namely the production of autoantibodies (Isenberg 
et al 2005). Since the discovery of autoantibodies more than 
50 years ago (Rose et al 1948; Holman and Kunkel 1957), 
these circulating autoantibodies are the key argument that 
B-cells play a pivotal role in the pathophysiology of many 
rheumatic diseases. However, B-cells can contribute in sev-
eral ways to the development of rheumatic diseases. First, 
B-cells are precursors of (auto-)antibody-secreting plasma 
cells. Secondly, they function as (auto-)antigen present-
ing cells, and, additionally, activated B-cells also produce 
cytokines (TNF-α, IL-6) that may inﬂ  uence the function of 
antigen-presenting dendritic cells. Thirdly, activated B-cells 
express costimulatory molecules, essential in the interaction 
with effector T-cells (Dorner and Burmester 2003).
Importantly, the detection of rheumatoid factor autoanti-
bodies (RF) and anti-cyclic citrullinated protein autoantibod-
ies (ACPA) are very speciﬁ  c ﬁ  ndings in RA patients (Gao 
et al 2005; Mimori 2005; van Gaalen et al 2005). RF autoan-
tibodies are directed against the Fcγ-tail of immunoglobulins 
and can form immune complexes. ACPA are directed against 
citrullinated peptides, which originate from the enzymatically 
conversion of arginine residues of proteins (Vossenaar and 
van Venrooij 2004). RA patients with circulating ACPA 
develop more joint damage over time (Kastbom et al 2004) 
and respond less favorably to anti-rheumatic therapies (Ales-
sandri et al 2004).
B-cell hyperactivity is considered a hallmark of auto-
immune disease, as was shown in SLE and SS (Llorente 
et al 1994; Lipsky 2001; Hansen et al 2004). Recently, a 
comprehensive, observational study in blood, bone marrow 
and synovium of RA patients showed similar characteristics 
of B-cell hyperactivity (Teng, Hashemi et al 2007). More-
over, inﬁ  ltration of B-cells and plasma cells are commonly 
observed in synovial biopsies from RA patients (Kruithof 
et al 2005; van Oosterhout et al 2005; Vos et al 2007). Still, 
the exact role of autoantibodies in the pathophysiology of 
RA remains unclear. Clinical studies from the beginning 
of 21st century already provided the important insight that 
eliminating RF autoantibodies by plasmapheresis or absorp-
tion by a column that speciﬁ  cally bind IgG (Prosorba) was 
unsuccessful in decreasing disease activity in RA (Gendreau 
2001). Therefore, these observations suggest that the efﬁ  cacy 
of B-cell depleting strategies in RA is based upon interference 
with the cellular functions of B-cells and/or the inhibition of 
differentiation into autoantibody producing cells.
B-cell depleting therapies
B-cell depletion can be achieved either by non-speciﬁ  c, high 
dose immunosuppression (Storek and Saxon 1992; Verburg 
et al 2001) or by speciﬁ  cally targeting B-cell speciﬁ  c mem-
brane proteins, such as CD20 and CD22 (Goldenberg 2006; 
Silverman 2006). High dose chemotherapy has been shown 
to induce signiﬁ  cant but temporary improvement of disease 
activity in RA patients (Snowden et al 2004), which was 
associated with signiﬁ  cant and long-lasting T-cell suppres-
sion in peripheral blood (Verburg et al 2001). Therefore, 
speciﬁ  c targeting of merely B-cells is a less toxic and less 
rigorous therapy, possibly with similar efﬁ  cacy in RA. In 
this respect, membrane proteins speciﬁ  c for B-cells are ideal 
targets for B-cell depleting therapies. Figure 1 shows several 
B-cell speciﬁ  c and non-speciﬁ  c membrane-bound proteins 
during B-cell development. It is obvious that targeting any 
of the B-cell speciﬁ  c proteins will target a large part but 
not the complete B-cell population. Currently, three agents, 
rituximab, HuMax-CD20 and epratuzumab, have been inves-
tigated to induce speciﬁ  c B-cell depletion but only the use 
of rituximab has been reported in RA patients.
Pharmacological aspects
of rituximab treatment in RA
Pharmacodynamic properties of rituximab are related to its 
speciﬁ  city for the CD20 membrane protein, found on the 
surface of B-cells. Although not fully elucidated, the cyto-
toxic effects of rituximab on CD20+ cells appear to involve 
complement-dependent cytotoxicity, complement-dependent 
cellular cytoxicity, antibody dependent cellular cytotoxocity 
and induction of apoptosis (Cerny et al 2002; Maloney et al 
2002; Smith 2003). The time to recovery of B-cells in periph-
eral blood is generally between 6 and 9 months (Edwards 
et al 2004a; Leandro, Cambridge et al 2006; Roll et al 2006). 
Recently, our group reported on the depleting effects of 
rituximab in peripheral blood, bone marrow and synovium 
of RA patients (Teng, Levarht et al 2007). Rituximab led to 
a rapid and complete depletion of all B-cells in peripheral 
blood. It was also shown that CD20+ B-cells in bone marrow 
were completely depleted at 12 weeks after therapy, in keep-
ing with a small study in 5 RA patients by Leandro, Cooper 
et al (2006). Still, not all CD19+ B-cells were eliminated in Biologics: Targets & Therapy 2007:1(4) 328
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bone marrow as pre-B-cells and CD20− plasma cells were 
not targeted. Lastly, we showed for the ﬁ  rst time that also 
in synovium all CD20+ B-cells, but not all CD79a+ B-cells, 
were eradicated (Teng, Levarht et al 2007). The latter is in 
line with the ﬁ  ndings of a previous study showing incomplete 
depletion of CD22+ B-cells in synovium (Vos et al 2007). 
In summary, it can be concluded that one treatment course 
consisting of 2 infusions of rituximab is able to completely 
deplete the subset of CD20+ B-cells, but not other B-cell lin-
eage cells such as plasma cells in bone marrow and synovium. 
Of note, data on B-cell counts after rituximab treatment 
should be carefully interpreted because recent studies have 
shown that rituximab can mask the CD20 epitope for other 
diagnostic anti-CD20 monoclonal antibodies used to identify 
B-cells (Teeling et al 2006; Teng, Ioan-Facsinay et al 2007). 
Therefore, it is crucial that other pan-B-cell markers, eg, 
CD19 or CD79a, are also reported.
One study has reported on the pharmacokinetics of 2 dos-
ages of 1g rituximab in 107 RA patients, of whom 37 patients 
also received intravenous cyclophosphamide and 36 patients 
oral methotrexate (Ng et al 2005). This study showed ritux-
imab had a distribution volume of 45 mL/kg with an average 
clearance rate of 276 mL/day. The half-life of rituximab after 
the ﬁ  rst infusion was 2.4 days and after the second infusion 
19.7 days. This difference in half-lifes can be explained by 
differences in the distribution of rituximab from the intravas-
cular to the extravascular compartment and to some extent by 
the different rate of elimination of the rituximab after binding 
to the CD20 membrane protein. The latter contrasted to data 
from lymphoma patients, in whom baseline B-cell values did 
affect clearance rate and distribution volume of rituximab. 
Importantly, this study also showed that clearance rate and 
distribution of rituximab were related to patients’ body sur-
face area (BSA), but that BSA could only explain 20% of the 
variability in clearance rate between patients. Furthermore, a 
study on the effects of BSA-adjusted dosage of rituximab in 
these patients showed only modest differences in exposure, 
indicating that BSA-adjusted dosage schemes for RA patients 
probably do not improve pharmacokinetic characteristics of 
rituximab (Ng et al 2005).
Efﬁ  cacy of rituximab in RA
Following several open-label studies of rituximab treat-
ment showing promising improvements in patients with 
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Figure 1 Expression of B-cell speciﬁ  c and non-speciﬁ  c markers during the differentiation of early progenitor B-cells into mature memory B-cells and/or plasma cells.Biologics: Targets & Therapy 2007:1(4) 329
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RA (Edwards and Cambridge 2001; Leandro et al 2002), 
Edwards et al conducted a randomized, placebo-controlled, 
multicenter trial to assess the efﬁ  cacy of rituximab as a single 
agent or in combination therapy with methotrexate or cyclo-
phosphamide. The study assessed 161 patients with RA, and 
compared the rituximab regimens with methotrexate alone 
(Edwards et al 2004b). The primary endpoint was deﬁ  ned 
as an ACR50 response (ie, a 50% or greater improvement in 
the signs and symptoms of RA, as deﬁ  ned by the American 
College of Rheumatology [ACR]) within 24 weeks. In this 
pivotal trial, 33% of the patients treated with rituximab alone 
achieved an ACR50 response, compared with 13% in the 
methotrexate group. The differences were even larger when 
combination therapy was used: 41% and 43% of patients 
achieved an ACR50 response when treated with rituximab 
in combination with methotrexate and cyclophosphamide, 
respectively. Naturally, more patients achieved an ACR20 
response (20% improvement) in this trial, the main results 
of which are summarized in Figure 2. Treatment with 
rituximab, particularly when combined with methotrexate, 
remained more efﬁ  cacious than methotrexate alone for at 
least 1 year. In addition, extension studies showed sustained 
beneﬁ  t from a single course of rituximab for up to 2 years 
(Strand et al 2005).
Further evidence for the efﬁ  cacy of rituximab in RA 
comes from the Dose-Ranging Assessment International 
Clinical Evaluation of rituximab in Rheumatoid Arthritis 
(DANCER) trial, which examined the efﬁ  cacy of differ-
ent doses of rituximab (500 mg bd vs 1000 mg bd on days 
1 and 15) and glucocorticoids in combination with stable 
doses of methotrexate (Emery et al 2006) (Figure 2). This 
trial conﬁ  rmed the previous positive effects of rituximab 
on RA disease activity. There was no difference in primary 
outcomes (ACR20 and ACR50 responses) between medium 
(500 mg) and high (1000 mg) doses of rituximab. How-
ever, using more stringent outcome measures (eg, ACR70 
response or remission deﬁ  ned by disease activity score) a 
trend in favor of high doses was observed. Furthermore, 
more patients developed circulating human anti-chimeric 
antibodies (HACA) when treated with medium doses 
(4.9% vs 2.7%). The DANCER study also demonstrated 
that corticosteroids administered during the ﬁ  rst 15 days of 
therapy (around the doses of rituximab) did not contribute 
to efficacy. However, intravenous methylprednisolone 
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Figure 2 Overview of the percentage of rheumatoid arthritis patients achieving an ACR20, ACR50, or ACR70 after rituximab treatment in three pivotal clinical trials: Edwards 
et al (2004b) (N = 160), DANCER trial (N = 465) (Emery et al 2006) and REFLEX-trial (N = 520) (Cohen et al 2006).Biologics: Targets & Therapy 2007:1(4) 330
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(100 mg iv before rituximab infusions) signiﬁ  cantly reduced 
the frequency of acute infusions reactions at the 1st infu-
sion (35% in the glucocorticoid-placebo group versus 25% 
in the glucocorticoid group), but not of the 2nd infusion at 
which time signiﬁ  cantly fewer infusions reactions occurred 
in general (5.6% in both groups).
More recently, the Randomized Evaluation of Long-term 
Efﬁ  cacy of rituximab (REFLEX) study also showed rituximab 
to be highly effective in patients with RA who had experienced 
an inadequate response to one or more TNF-blocking agents 
(Cohen et al 2006). In this trial 520 refractory RA patients 
were randomized to methotrexate alone or the combination 
of methotrexate with rituximab. Although this study deﬁ  ned 
its primary endpoint as an ACR20 improvement (summarized 
in Figure 2), the signiﬁ  cantly larger proportion of RA patients 
that achieved an ACR50 improvement with rituximab and 
methotrexate (27%) as compared to methotrexate alone (5%) 
is more illustrative for comparison and conﬁ  rms the efﬁ  cacy 
achieved in the ﬁ  rst trial of Edwards et al. Moreover, this study 
was able for the ﬁ  rst time to measure a trend towards slower 
radiographic progression within 24 weeks in patients treated 
with rituximab (change in total Genant-modiﬁ  ed Sharp score 
of 0.6 ± 1.9) in comparison to the methotrexate alone group 
(change in total Genant-modiﬁ  ed Sharp score of 1.2 ± 3.3; 
p = 0.17). This was further corroborated after 1 year, when 
progression was signiﬁ  cantly lower in the rituximab-treated 
group (change in radiographic score: 2.31 vs 0.99; p = 0.004) 
(Keystone, Emery et al 2006).
Interestingly, preliminary data indicate that RA patients 
can be successfully retreated with rituximab. The efﬁ  cacy 
of repeated courses of rituximab did not seem to differ from 
the ﬁ  rst treatment course (Pavelka et al 2005; Keystone, 
Fleischmann et al 2006).
Safety and tolerability
Rituximab has been used in the general hematological 
practice for more than 10 years. Long-term safety is well 
established in these patients: no increased incidence of 
infections has been observed and most infections were typi-
cal of those common in normal hosts (McLaughlin 2001). 
Safety data for rheumatologic patients are thus far limited 
and conclusions can only be drawn for the short-term 
adverse events. Most of the side effects are seen during 
the intravenous administration and consist of mild symp-
toms (nausea, fever, headache, myalgia). In the DANCER 
phase-II trial reported 38% (73 of 192 patients) of the RA 
patients experienced infusion-related side effects while in 
the REFLEX-trial this was 23% (72 of 308 patients) using 
1000 mg rituximab. Signiﬁ  cantly fewer side effects were 
observed at the second infusion: in DANCER 10% (19 of 192 
patients) and in REFLEX 8% (26 of 308 patients). This can 
be explained by desensitization due to the fact that rituximab 
can still be measured in serum at low concentrations when 
the second infusion is administered. Furthermore, a study 
evaluating the concomitant administration of corticosteroids 
before the infusion of rituximab showed that corticosteroids 
did not affect the outcome of patients, but did decrease the 
incidence of infusion-related side effects in one third of the 
patients (Fleischmann et al 2005).
With respect to infectious complications (Table 2), a 
non-signiﬁ  cant increased incidence of 35% was reported in 
rituximab treated group versus 28% in the placebo group 
from the DANCER study. The type and severity of infec-
tions were similar in both groups, mostly being respiratory 
tract infections (7%), urinary tract infections (3%) and 
nasopharyngitis (6%). Serious infections were not common 
and occurred in 1%–2% of the patients. When accumulat-
ing data from the REFLEX-trial, an incidence of infections 
of 41% was observed as compared to 38% in the placebo 
group. The calculated rate of infection per 100 patient years 
was actually lower in the rituximab treated group (154.6 in 
the placebo group versus 138.2 infections per 100 yrs in the 
rituximab treated group). Regarding serious infections there 
was a trend to a higher incidence in patients treated with 
Table 2 Rate of infectious events in two pivotal, double-blinded, randomized trials assessing efﬁ  cacy of rituximab in RA patients
DANCER trial (N = 209 vs 308) Placebo (N = 149) RTX 2 × 500 mg (N = 124) RTX 2 × 1000 mg (N = 192)
Total patient years n.a. n.a. n.a.
Incidence of infections 28% 35% 35%
Infections per 100 patient yrs n.a. n.a. n.a.
Serious infections per 100 patient yrs 3.19 0 4.74
REFLEX trial Placebo (N = 209) RTX 2 × 1000 mg (N = 308)
Total patient years 82.1 134.6
Incidence of infections 38% 41%
Infections per 100 patient yrs 154.6 138.2
Serious infections per 100 patient yrs 3.7 5.2Biologics: Targets & Therapy 2007:1(4) 331
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rituximab (3.7 in the placebo group versus 5.2 infections 
per 100 years in the rituximab treated group). Collectively, 
these short-term data suggest that a single treatment course 
with rituximab does not increase the incidence of infectious 
complications, which suggests that during B-cell depletion 
the innate immune system as a “ﬁ  rst-line defense”, including 
natural killer cells and T-cells, as well as circulating antibod-
ies and long-lived plasma cells provide adequate protection 
to exogenous antigens (McLaughlin 2001).
Lastly, B-lymphocyte depletion is an anticipated side 
effect of rituximab and the time to reconstitution differs for 
each patient and for each underlying rheumatic disease. The 
mean time to reconstitution is around 6–9 months (Edwards 
et al 2005). A decrease of serum concentration of immu-
noglobulins (IgG, IgM, IgA) below normal values seldom 
occurs. Also, long-term humoral memory derived from long-
lived plasma cells, as measured by serum antibodies against 
the recall antigen tetanus toxoid, does not seem to be affected 
by a single treatment course of rituximab.
Patient-focused perspectives
Few studies so far have addressed patients’ satisfaction and 
acceptability of rituximab treatment, although new data will 
appear. One spin-off study from the REFLEX-trial investi-
gated quality of life as measured by the SF-36. This study 
showed that rituximab resulted in a signiﬁ  cantly greater 
improvement in quality of life scores on all 8 domains of the 
SF-36 (Kielhorn et al 2006). In addition, two cost-analysis 
studies performed by the Health Economics and Strategic 
Pricing of F.Hoffmann-La Roche (Alvarez et al 2006; Lewis 
et al 2006), the pharmaceutical company producing ritux-
imab, showed by a Markov Model that rituximab combined 
with methotrexate could achieve a gain of 0.48–0.63 Quality 
Adjusted Life Years (QALYs) as compared to current practice 
for refractory RA patients, which included TNF-blocking 
treatment. Importantly, these analyses compared treatments 
over an average time of approximately 18.5 years. Clearly, 
these studies need to be reproduced with adequate control 
groups as well as by independent groups, to enable relevant 
socioeconomic evaluations.
Conclusions
Anti-CD20-mediated B-cell depletion by rituximab has 
proven to be a valuable expansion of the therapeutic arma-
mentarium in the rheumatologic practice. Several studies 
have now established its efﬁ  cacy and safety for treating 
refractory RA patients. Based on the evidence from three 
large randomized trials, rituximab treatment is a treatment 
option for RA patients failing TNF-blocking therapy. Future 
studies will have to show whether B-cell depletion is supe-
rior to TNF-blocking therapy in earlier stages of disease. 
In addition, the exact mechanism through which rituximab 
treatment results into clinical improvement still needs to be 
clariﬁ  ed. Recent studies have made it clear that depletion of 
CD20+ B-cells has led to signiﬁ  cant decreases of autoanti-
body titers, but the biologic relevance of these observations 
is still unclear. Undoubtedly, as rituximab will be more and 
more prescribed by rheumatologists, further insight into the 
effects of B-cell depletion will be revealed. Lastly, studies 
analyzing cost-effectiveness will determine for a large part 
the availability of rituximab for RA patients in the near future 
and studies deﬁ  ning predictive factors of responsiveness to 
rituximab may therefore be of high importance. Recently, 
one study identiﬁ  ed predictive determinants in serum and 
synovium of RA patients who have a high a-priori change 
to achieve a good response upon rituximab treatment (Teng, 
Levarht et al 2007). Because of increasing expenses to pro-
vide biologic treatments, such as rituximab, to RA patients, 
these studies obviously need to be further substantiated.
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